Management of breast lobular carcinoma in situ: radio-pathological correlation, clinical implications, and follow-up

Purpose of investigation: to show management of patients with breast lobular carcinoma in situ (LCIS). Materials and Methods: This study is the retrospective review of 65 patients, between 1996 and 2012, with isolated LCIS of the breast, evaluated through clinical examination, ultrasound, and mammography at the first examination and follow-up. Results: In 53 patients (81.54%), clinical examination was negative. In 14/65 (21.54%) cases, ultrasound was positive and led to biopsy. The clusters of tiny calcifications were the predominant mammographic pattern (45 cases, 69.23%). Forty-six patients (70.77%) underwent surgical biopsy after guided stereotactic placement of metallic marker (hook-wire), 12 (18.46%) by stereotactic vacuum biopsy (SVB), 5 (7.69%) by core needle biopsy (CNB) under ultrasound guidance, two (3.08%) patients CNB with clinically palpable nodules. Fourteen (21.54%) women underwent a quadrantectomy or total mastectomy after the first diagnosis; in this latter group follow-up was negative. Among the 51 patients (78.46%) who did not undergo quadrantectomy or total mastectomy, five relapses occurred, respectively, three LCIS and two infiltrating ductal carcinomas (IDC). Follow-up ranged from 12 to 144 months. Conclusion: LCIS is a risk factor for invasive carcinoma and should be managed with careful follow-up, but if there is a discrepancy between pathology and imaging, surgical excision is mandatory.

Lobular carcinoma in situ (LCIS); Breast cancer; Follow-up; Lobular intraepithelial neoplasia (LIN); Management.

[1] Venkitaraman R.: “Lobular neoplasia of the breast”. Breast J., 2010, 16, 519.

[2] Lakhani S. R., Audretsch W., Cleton-Jensen A.M., Cutuli B., Ellis I., Eusebi V., et al: “The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?” Eur. J. Cancer, 2006, 42, 2205.

[3] Beute B.J., Kalisher L., Hutter R.: “Lobular carcinoma in situ of the breast: clinical, pathologic and mammographic features”. A.J.R., 1991, 157, 257.

[4] Hutter R.P., Snyder R.E., Lucas J.C., Foote F.W.Jr., Farrow J.H.: “Clinical and pathologic correlation with mammographic findings in lobular carcinoma in situ”. Cancer, 1969, 23, 826.

[5] Pope T.L., Fechner R.E., Wilhelm C.M., Wanebo H.J., deParedes E. S.: “Lobular carcinoma in situ of the breast: mammographic features”. Radiology, 1988, 168, 63.

[6] Snyder R.E.: “Mammography and lobular carcinoma in situ”. Surg. Gynecol. Obstet., 1996, 122, 260.

[7] Arpino G., Laucirica R., Elledge R.M.: “Premalignant and in sity breast disease: biology and clinical implications”. Ann. Intern. Med., 2005, 143, 446.

[8] Sonnenfeld M.R., Frenna T.H., Weidner N., Meyer J.E.: “Lobular carcinoma in situ: mammographic pathologic correlation of results of needle-directed biopsy”. Radiology, 1991, 181, 363.

[9] Foote F.W., Stewart F.W.: “Lobular carcinoma in situ: a rare form of mammary cancer”. Am. J. Pathol., 1941, 17, 491.

[10] Haagensen C.D., Lane N., Lattes R., Bodian C.: “Lobular neoplasia (so-called lobular carcinoma in situ) of the breast”. Cancer, 1978, 42, 737.

[11] Liebens F., Cardinael A.S., Schillings A.P., Mendez V., Demoulin C., Cusumano P. et al.: “Current management of lobular in situ”. J.B.R.-B.T.R., 2008, 91, 166.

[12] Lu Y.J., Osin P., Lakhani S.R., Di Palma S., Gusterson B.A., Shipley J.M.: “Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia”. Cancer Res., 1998, 58, 4721.

[13] Hwang E.S., Nyante S.J., Yi Chen Y., Moore D., DeVries S., Korkola J.E., et al.: “Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma”. Cancer, 2004, 100, 2562.

[14] Page D.L., Dupont W.D., Rogers L.W.: “Ductal involvement by cells of atypical lobular hyperplasia in the breast: a long-term follow-up study of cancer risk”. Hum. Pathol., 1988, 19, 201.

[15] Elsheikh T.M., Silverman J.F.: “Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature”. Am. J. Surg. Pathol., 2005, 29, 534.

[16] Goldstein N.S., Vicini F.A., Kestin L.L., Thomas M.: “Differences in the pathologic features of ductal carcinoma in situ of the breast based on patient age”. Cancer, 2000, 88, 2553.

[17] Page D.L., Dupont W.D., Rogers L.W., Rados M.S.: “Atypical hy-perplastic lesions of the female breast. A long-term follow-up study”. Cancer, 1985, 55, 2698.

[18] Dupont W.D., Page D.L.: “Risk factors for breast cancer in women with proliferative breast disease”. N. Engl. J. Med., 1985, 312, 146.

[19] Page D.L., Kidd T.E. Jr., Dupont W.D., Simpson J.F., Rogers L.W.: “Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease”. Hum. Pathol., 1991, 22, 1232.

[20] Eusebi V., Magalhaes F., Azzopardi J.G.: “Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation”. Hum. Pathol., 1992, 23, 655.

[21] Sneige N., Wang J., Baker B.A., Krishnamurthy S., Middleton L.P.: “Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases”. Mod. Pathol., 2002, 15, 1044.

[22] Bratthauer G.L., Tavassoli F.A.: “Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clini-cal implications”. Virchows Arch., 2002, 440, 134.

[23] Warner E., Yaffe M., Andrews K.S., Russell C.A., Morris E., Pisano E. et al.: “American Cancer Society Guidelines for Breast Screening with MRI as an adjunct to Mammography”. C.A. Cancer J. Clin., 2007, 57, 75.

[24] Menon S., Porter G.J.R., Evans A.J., Ellis I.O., Elston C.W., Hodi Z., et al.: “The significance of lobular neoplasia on needle core biopsy of the breast”. Virchows Arch., 2008, 452, 473.

[25] Port E.T., Park A., Borgen P.I., Morris E., Montgomery L.L.: “Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia”. Ann. Surg. Oncol., 2007, 14, 1051.

[26] Esserman L.E., Lamea L., Tanev S., Poppiti R.: “Should the extent of lobular neoplasia on core biopsy influence the decision for excision?” Breast J., 2007, 13, 55.

[27] Hwang H., Barke L.D., Mendelson E.B., Susnik B.: “Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: routine excision is not necessary”. Mod. Pathol., 2008, 21, 1208.

[28] Fisher E.R., Land S.R., Fisher B., Mamounas E., Gilarski L., Wolmark N.: “Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ”. Cancer, 2004, 100, 238.

[29] Ansquer Y., Santulli P., Colas C., Jamali M., Tournigand C., Duper-ray L., et al.: “Lobular intra-epithelial neoplasia: atypical lobular hyperplasia and lobular carcinoma in situ”. J. Gynecol. Obstet. Biol. Reprod., 2010, 39, 91.

[30] Nagi C.S., O’Donnell J.E., Tismenetsky M., Bleiweiss I.J., Jaffer S. M.: “Lobular neoplasia on core needle biopsy does not require excision”. Cancer, 2008, 112, 2152.

[31] Destounis S.V., Murphy P.F., Seifert P.J., Somerville P.A., Arieno A. L., Morgan R.C. et al.: “Management of patients diagnosed with lobular carcinoma in situ at needle core biopsy at a community-based outpatient facility”. A.J.R., 2012, 198, 281.